Probabilistic sensitivity analysis (PSA) demonstrates the parameter uncertainty in a decision problem. The technique involves sampling parameters from their respective distributions (rather than simply using mean/median parameter values). Guidance in the literature, and from health technology assessment bodies, on the number of simulations that should be performed suggests a 'sufficient number', or until 'convergence', which is seldom defined. The objective of this tutorial is to describe possible outcomes from PSA, discuss appropriate levels of accuracy, and present guidance by which an analyst can determine if a sufficient number of simulations have been conducted, such that results are considered to have converged. The proposed approach considers the variance of the outcomes of interest in cost-effectiveness analysis as a function of the number of simulations. A worked example of the technique is presented using results from a published model, with recommendations made on best practice. While the technique presented remains essentially arbitrary, it does give a mechanism for assessing the level of simulation error, and thus represents an advance over current practice of a round number of simulations with no assessment of model convergence.
There are a number of techniques by which model convergence can be assessed, our preferred being the running of the model until the 95% confidence interval for the incremental net monetary benefit does not include zero.
For convenience, we have made available for download a worked example of how convergence may be demonstrated in probabilistic analysis
Probabilistic Sensitivity Analysis in Health Economics
Probabilistic sensitivity analysis (PSA) is a method for accounting for parameter uncertainty in cost-effectiveness models. A distribution is assigned to each parameter, reflecting uncertainty in the true value, accounting for the correlation between parameters where possible. Samples are then repeatedly drawn from each distribution and used as model inputs. Each unique set of inputs (a single 'simulation vector') results in a unique set of model outputs. Considering the results of many simulations allows for estimation of the expected (mean) model outputs and the uncertainty around these outputs [1, 2] . PSA is mandated by many health technology assessment (HTA) agencies internationally, including the UK's National Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH) [3, 4] . It is also recommended in guidelines published by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and the Society for Medical Decision Making (SMDM) [5] . The reason for this requirement is in non-linear models; results based only on a fixed selection of input values will be biased. Common reasons for this are the use of median values where the median value does not equate to the mean value in the underlying distribution (such as a lognormal distribution), and where simultaneously changing multiple parameters may alter the proportion of patients simulated to experience health states associated with large cost-utility impacts. Only through probabilistic analysis can the true results of non-linear models be identified.
To illustrate the importance of using probabilistic analysis, a PSA was conducted using 250,000 simulations in a published model [6] ; this large number is assumed to give close approximations of 'true' incremental cost-effectiveness ratios (ICERs). While the deterministic ICER was £25,961, the probabilistic estimate was £20,684, showing the difference that can occur between the two in non-linear models. This was followed by a series of 20 additional PSAs where, for each of this series, the mean ICER was calculated separately over simulations 1 to n, for n = 1-10,000, allowing for consideration of change in the mean as the number of simulations increases. As the number of simulations increases, the range of the mean ICERs across the series of PSAs narrows (Fig. 1) . After 1000 simulations, the mean ICERs converged to within £500 of the estimated 'true' ICER in all 20 PSAs, but only 12 of 20 had converged to within £250. Running more simulations, 17 of the 20 had converged to within £250 at 5000 simulations, with all 20 having done so by 10,000 simulations.
Common presentations of PSA results include tabulation of mean model outputs and the probability that the intervention is cost effective at plausible cost-effectiveness thresholds, scatterplots of simulations on the cost-effectiveness plane, and cost-effectiveness acceptability curves (CEACs) and frontiers (CEAFs) [7, 8] . These allow for consideration of the mean and distribution of model outputs [9] and may be used to inform value of information analysis [10] .
Since PSA requires random sampling from distributions, the parameter inputs will differ each time the PSA is repeated across equal numbers of simulations, such that the model outputs will also differ. In cohort models (the form of models we address in this tutorial), it follows that there are two uncertainties: the distribution of outputs across simulations within a PSA, and the difference between mean outputs across PSAs that reflect random noise (i.e. Monte Carlo error). The first type of uncertainty is what PSA aims to estimate, but the second type of uncertainty is undesirable. Fortunately, the greater the number of simulations conducted, the smaller the Monte Carlo error; if this error is sufficiently small, then the results are said to have 'converged' as the error is considered inconsequential.
Widespread convention in current practice is to conduct between 1000 and 10,000 simulations, with no evidence presented on model convergence. Equally, no specific guidance on convergence is currently provided by HTA agencies. Although conducting more simulations would generally reduce the Monte Carlo error, this increases the computational resources required and adds little value if convergence has already been reached. It follows that current practice is problematic; if too few simulations are conducted then the PSA results may incorporate substantial Monte Carlo error, but if too many simulations are conducted then the PSA is computationally inefficient. Without justification for the analysis performed, it is not possible to know where on this spectrum the analysis lies.
The objective of this tutorial is to consider how model convergence can be considered in practice in cohort models (individual patient models are the topic of a separate literature). The topic is illustrated using the published example of chondrocyte implantation for cartilage damage of the knee [6] . 
Potential Outcomes of Interest
In addition to the complexity of the economic model itself, the number of simulations required for convergence of any given model depends upon the outcomes of interest to the decision maker and the desired level of accuracy for each outcome.
The most commonly considered model output is the ICER, typically the cost per quality-adjusted life-year (QALY) gained. If the decision maker requires only an estimate of the mean ICER, the number of simulations should be just sufficient for this statistic to converge. Additional simulations may be required beyond the number required for the ICER statistic to converge if outputs other than the mean ICER are of interest to the decision maker [11, 12] . For example, the decision maker may be interested in a confidence interval (CI) for the ICER estimate, the probability an intervention's cost-effectiveness falls below a certain threshold, or the expected value of perfect information (EVPI) of an intervention. Alternatively it may be important that the estimated distributions of the model outputs are accurate between PSAs, and not merely the mean ICER alone. This may require additional simulations to ensure convergence towards the edges of each distribution that are inherently less stable than the mean.
An alternative outcome is the incremental net monetary benefit (INMB) statistic, a positive value that signifies a technology is cost effective [13, 14] . While ICERs may be more frequently used in decision making, the net-benefit statistic has a number of desirable properties compared with the ICER. Most importantly, the moments of its distribution are defined theoretically, such that it is possible to define a variance mathematically, and the assumption of a normal sampling distribution is reasonable under conditions imposed by the central limit theorem. By contrast, the ICER, as a ratio of two random variables, does not have a mathematically tractable variance.
For these reasons, we focus on net-benefit quantities in this tutorial in order to assess the convergence of important outcomes for the purposes of cost-effectiveness decision making, while recognising that the analyst may want to convert back to the use of the ICER when presenting the results of their cost-effectiveness analysis.
Appropriate Level of Accuracy
The desired level of accuracy for each outcome depends on the context. Models accompanying HTA submissions should exhibit a high degree of accuracy since they influence funding decisions. A high degree of accuracy is also desirable for a journal article that becomes a part of the scientific record. Conversely, a low degree of accuracy may be sufficient for an early model during the development of a technology, or for a technology for which increased precision would not change the funding decision. For example, increased precision in a mean ICER estimated to be between £120,000 and £130,000, where the willingness to pay threshold (λ) is £30,000 per QALY, would be superfluous to requirements.
Ideally the decision maker would specify not only the outcomes of interest but also the desired level of accuracy. This could be defined in terms of standard errors (SEs) around the mean ICER, or absolute levels of accuracy, e.g. ICERs to be reported within a tolerance of ± £500. A further request may also be for the probability an intervention is cost effective, although in isolation these may be misleading, with funders typically preferring mean ICER [15] . For convenience, the formulae for the CI of the INMB and probability of being cost effective at a given threshold are given in Table 1 .
Defining Convergence
For a linear model, the deterministic outputs represent the 'true' values and the mean outputs in a PSA will converge towards these values. It follows that the outputs of interest may be considered to have converged when they have stabilised (given the desired level of accuracy) to the respective deterministic outputs (i.e. the mean ICER has stabilised to within the specified accuracy of the deterministic ICER).
For a non-linear model, the deterministic outputs will provide biased estimates of the 'true' values. The 'true' values can only be estimated empirically; as the number of simulations increases, the mean outputs in the PSA will converge towards these 'true' values (although, by definition, these 'true' values will never be observed). It follows that the outputs of interest may be considered to have converged when they have stabilised sufficiently close to the outputs Probability of being cost effective, given λp ± Z 1− √̂p ±(1−p) n that would be observed if an infinite number of simulations were to be performed. Regardless of the model type, each mean output in the PSA will fluctuate as the number of simulations increases, stabilising close to the 'true' value of the output. During this period of fluctuation, it is possible for a mean output to remain stable temporarily, or to lie close to the 'true' value by chance, only to diverge away as the number of simulations increases. To ensure convergence, it follows that it is not appropriate to halt a PSA immediately upon observing that a mean output appears stable, and more robust methods are required.
In determining convergence, visual aids have been used previously in HTA submissions and journal publications, and can be an effective form of communicating how the level of uncertainty varies [16] [17] [18] . However, interpretation of visual aids is subjective and may imply stability (or instability), dependent on the scales of the plot chosen.
Our suggested approach for determining when outputs have converged makes use of the INMB outcome by determining a CI around the mean outcome. The CI around the point estimate of the INMB can then be translated to a CI around the point estimate of the ICER for presentation to a decision maker. To do this, the value of λ is varied until one of the CI limits for the INMB becomes zero. The value of λ is then equivalent to one of the limits of the CI around the ICER. Repeating this process for the other limit around the INMB yields an associated CI around the ICER. The choice of significance level will depend on the decision problem, however for simplicity we suggest this should be 5% or less, as is current standard convention in the medical field.
INMB is chosen specifically to avoid mathematical limitations of interpreting the uncertainty around the point estimate of a ratio, such as the ICER. The INMB is normally distributed (and therefore its variance is well-defined) provided that the incremental costs and QALYs each follow a normal distribution (per the Central Limit Theorem, assuming a large, i.e. n > 30, number of simulations). The variance around the point estimate of the ICER is undefined, and hence convergence of the ICER is not determined directly.
Based on this property of the INMB, the variance may be estimated within standard software such as Microsoft Excel ® , and hence the SE of the point estimate of the INMB may also be determined using the sample variance and the number of simulations. Thus, a CI around the point estimate of the INMB may be determined and is interpretable.
For an adoption decision, if after a given number of simulations the CI of the INMB does not contain zero, no further simulations are required, i.e. increased precision of the point estimate of the INMB would be very unlikely to change the decision made. Conversely, if the CI still contains zero after a given number of simulations, further simulations would be required to produce a CI that excludes zero. In the case of cohort models that have short computational times, this is not anticipated to create a burden unless the true ICER was equal to λ.
For decision makers, the ICER is most frequently used to present the results of cost-effectiveness analysis. As such, it is of interest to be able to present the uncertainty around the ICER itself, particularly for decision makers, where λ is either undefined (e.g. the Scottish Medicines Consortium [SMC]) or lies within a range (e.g. NICE) [4, 19] . The value of λ at which the INMB is zero represents the point estimate of the ICER. The uncertainty in the INMB can be translated into the uncertainty in the ICER by identifying the values of λ at which the lower bound of the INMB is zero and the upper bound of the INMB is zero. These values may be found by trial and error or may be calculated using the 'goal seek' functionality within Microsoft Excel, or with similar mathematical programming functions in other software (such as the 'lpSolve' or 'nloptr' packages in the statistical analysis software R).
Worked Example
For our proposed approach, we considered the number of simulations required for the mean ICER to converge in our example model. The mean ICER should be calculated as the quotient of the mean incremental costs and QALYs over the number of simulations considered (i.e. not the mean of individually calculated ICERs for each simulation).
Following our recommended approach, the value of λ may be defined. Assuming a λ of £20,000, and a significance level of 5%, the resultant point estimate and CI of the mean INMB achieved after 500 simulations is − £120 (95% CI − £687 to £447). As this CI includes zero, the conclusion drawn is that a larger number of simulations are required. Increasing the number of simulations to 1000 yields a result of − £426 (95% CI − £825 to − £27). As this CI no longer contains zero, 1000 simulations may be considered sufficient in this example as the adoption decision would be unlikely to change should an increased number of simulations be performed.
However, λ may not be defined. In this case, let us assume the decision maker is interested in obtaining an ICER within a maximum tolerance of ε = £500 in either direction. The associated point estimate (95% CI) around the ICER is £20,181 (£19,427-£20,943). Given the width of this CI is greater than £1000, further iterations would be required. For 1000 iterations, the results are £20,575 (£20,035-£21,140). This width is close to £1000, but is not smaller, therefore an increased number of simulations are required. Using 1500 simulations provides a result of £20,564 (£20,125-£21,027), and, hence, with a width of less than £1000, this number of simulations would be considered sufficient.
If an appropriate λ and ε are not available from decision makers, a reasonable value should be made in relation to the decision problem. For example, if after 1000 simulations the resultant ICER is £30,000, an appropriate choice of ε may be ε = £500 in either direction, whereas if after 1000 simulations the resultant ICER is £50,000, an appropriate choice of ε may be ε = £1000 in either direction. Although crude, this approach allows for consideration of the Monte Carlo error and provides guidance as to the number of simulations required for convergence.
While these examples of ε may appear arbitrary, it represents an advance over current practice, under which an arbitrary number of simulations is conducted with no consideration as to whether convergence has been reached. When specifying ε, we are able to have confidence the true value is in the region of ε, as opposed to running an arbitrary number of simulations when we are not able to conclude to what degree of accuracy the model has converged.
Acknowledgement of Other Methods
Several other methods have also been used to define convergence. The methods we believe to be most relevant are the jackknife and Taylor series estimates of the SE around the point estimates of the ICER. The jackknife was proposed by Efron [20] to give an approximate mean and variance of a parameter of interest. The Taylor series is statistically more efficient than the jackknife [21] , and is an expansion of a function into an infinite sum of its terms-by taking the first n terms of a series, it then uses a derivative of this function to determine the likely form from which minima and maxima can be estimated.
Both the jackknife and Taylor series methods make the assumption that the SE of the point estimate of the ICER may be calculated, assuming normality in the distribution of the mean ICER and therefore disregarding the skewness of the distribution. For this reason, these methods are not recommended in case either component of the ICER approaches zero, where this assumption of normality will not hold. If applied to the INMB, these approaches provide near-identical results to the assumption of normality (our proposed method) in a simulation study (data not shown).
There may be a situation that calls for very accurate estimates of model results (e.g. for a model with high budgetary impact with an ICER lying close to λ). In these rare cases, the use of a large number of simulations presents a valid (although crude and computationally burdensome) approach to defining convergence. Importantly, the timeliness of producing results in general is paramount in decision making, leading to us not recommending this approach as in many situations it would not be possible to undertake within a restricted timeframe.
Recommendations
In this tutorial, we have considered the appropriate number of simulations to conduct in PSA. Current practice is to use an arbitrary number of simulations, regardless of the model's complexity-this 'one size fits all' approach is not ideal and may result in substantial Monte Carlo error or wasted computational resources (and no possibility of determining which is the case). Using the recommended method highlighted in this tutorial, it is possible to consider the number of simulations required for the outcome of interest to converge to the desired degree of accuracy. Although our example focussed on the INMB and ICER, these methods generalise to other outcomes of interest.
Due to differences in the complexity of models, it is not possible to recommend a specific number of simulations to be used in all circumstances. Furthermore, the outcomes of interest and accuracy required may (legitimately) vary between decision makers. Some decision makers may desire precise estimates of multiple model outputs, whereas others may only be interested in whether the mean ICER is above or below the threshold (λ). We therefore recommend that decision makers explicitly identify the outcome(s) of interest and the desired degree of accuracy where possible. In the absence of such guidance, analysts should adopt a transparent and methodical approach to defining an appropriate level of convergence. This also applies to EVPI (an umbrella term that incorporates partial EVPI), where the more stable the ICER, the more precise the resulting EVPI. Equally, the PSA runs required to reduce the CI around the INMB will ensure sufficient data are available for non-parametric regression methods in partial EVPI [22, 23] .
The method detailed in this tutorial provides a general guide to providing an informed demonstration of model convergence, via the use of a CI around the point estimate of the INMB or ICER. The method proposed exhibits clear advantages over other methods, through the avoidance of mathematical issues pertaining to the derivation of the variance of a ratio (which is undefined) or subjective interpretation of visual plots. Visual plots may serve as a useful complement to intuitively demonstrate convergence (as in Fig. 1 ), but should not be relied upon alone. Depending on the decision problem, an increased level of precision (e.g. the use of a 99% CI) may be preferable. However, the derivation of a 99% CI around the mean ICER may be time-consuming if the 'true' ICER lies close to λ; therefore, ascertaining a CI with greater precision should be undertaken with caution. The reason for this is, towards the edges of a distribution the uncertainty can be profound, with values highly unstable and, by definition, rarely sampled-the 'cost' in computing power to obtain this range may be prohibitive.
Conclusions
The de facto standard of 1000-10,000 simulations may be sufficient in some circumstances, however this is not guaranteed. This is particularly the case where the distribution of an outcome is of interest to the decision maker, rather than simply the mean. Although modellers should be encouraged to choose an appropriate method for demonstration of convergence, in the majority of cases we expect the proposed approach will suffice. A Microsoft Excel workbook with a worked example of our method for calculating the mean value can be freely downloaded at http://www.delta hat.co.uk/resou rces/psa
The approach we propose does have limitations and remains, to some degree, arbitrary in its level of accuracy. However, more important than the exact method used is that the issue of convergence be considered in probabilistic analysis and documented appropriately. Until this is widely done, there is the very real possibility of undiagnosed inaccuracy in the results, which could in turn affect decision making.
Data Availability Statement
The methods used in this paper are publicly available and referenced. A worked example of our proposed method can be downloaded at http://www.delta hat.co.uk/resou rces/psa.
